Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the…
Read the full articleYou might also wanna read
$2.5 Million Department of Defense Grant Funds Development of Targeted Therapy for Triple-Negative Breast Cancer
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer si
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
Conditions : Breast Cancer (Triple Negative Breast Cancer (TNBC)) Interventions : Other: Non interventional study Sponsors : Assistance Publ
The immunology of human breast cancer
Immunotherapy with ICIs transforms melanoma & lung cancer care, but most breast cancers, except triple-negative ones, resist. PMID:42151556,
Susan G. Komen® Awards $15.4 Million In Research Grants to Accelerate Breakthroughs in Breast Cancer Care
Lisa Coussens, Ph.D., is among the recipients of a Leadership Grant from the Susan G. Komen Foundation.
CMU-Q Researchers Discover Genetic Molecule That May Suppress Breast Cancer Tumors
Researchers at Carnegie Mellon University in Qatar (CMU-Q) have discovered a genetic molecule that could provide new approaches to treating
cmu.edu·3d agoDiscovering How Stem T Cells Sustain Immune Defenses During Chronic Disease – Weill Cornell Medicine
Weill Cornell Medicine shared a post on LinkedIn: “A collaborative team from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Cent
Comments
Sign in to join the conversation.
No comments yet. Be the first.